One single dose of 200 μg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy

Transfusion

Volumn 48, Issue 8, 2008, Pages 1721-1729

  Koelewijn, Joke M ^c   De Haas, Masja ^c   Vrijkotte, Tanja G M ^c   Bonsel, Gouke J ^c   Van Der Schoot, C Ellen ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH PROGRAM; HEMOLYTIC ANEMIA; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; PREGNANCY; PREVALENCE; PROPHYLAXIS; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SINGLE DRUG DOSE;

ERYTHROBLASTOSIS, FETAL; FEMALE; HUMANS; INFANT, NEWBORN; ISOANTIBODIES; NETHERLANDS; PARITY; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RETROSPECTIVE STUDIES; RH ISOIMMUNIZATION; RHO(D) IMMUNE GLOBULIN; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEROEPIDEMIOLOGIC STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 48249088516     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01742.x     Document Type: Article

References (34)

1. Bowman JM. RhD hemolytic disease of the newborn. N Engl J Med 1998 339 : 1775 7.
2. Levine P, Burnham L, Katzin EM, Vogel P. The role of iso-immunization in the pathogenesis of erythroblastosis fetalis. JAMA 1941 113 : 126 7.
3. Mollison PL, Engelfriet CP, Contreras M. Haemolytic disease of the fetus and the newborn. In : Mollison PL, Engelfriet CP, Contreras M, editors. Blood transfusion in clinical medicine. 10th ed. Oxford : Blackwell Science 1997 390 424.
4. Daniels G. Blood group antibodies in haemolytic disease of the fetus and newborn. In : Hadly A, Soothill P, editors. Alloimmune disorders of pregnancy. Cambridge : Cambridge University Press 2002 21 40.
5. Kumpel BM. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion 2006 46 : 1652 6.
6. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000 14 : 44 61.
7. Committee prevention pregnancy immunization. Prevention of pregnancy immunization. The Hague : Dutch Health Council 1992 1992/08 : 50 [Report in Dutch].
8. Bowman JM, Chown B, Lewis M, Pollock JM. Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc 1978, 623 7.
9. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks'-gestation service program. Can Med Assoc J 1978 118 : 627 30.
10. Tovey LA, Townley A, Stevenson BJ, Taverner J. The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. Lancet 1983 2 : 244 6.
11. Hermann M, Kjellman H, Ljunggren C. Antenatal prophylaxis of Rh immunization with 250 micrograms anti-D immunoglobulin. Acta Obstet Gynecol Scand Suppl 1984 124 : 1 15.
12. Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfus Med Rev 1987 1 : 101 12.
13. Huchet J, Dallemagne S, Huchet C, Brossard Y, Larsen M, Parnet-Mathieu F. Ante-partum administration of preventive treatment of Rh-D immunization in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicenter study carried out in the Paris region. J Gynecol Obstet Biol Reprod 1987 16 : 101 11.
14. Trolle B. Prenatal Rh-immune prophylaxis with 300 micrograms immune globulin anti-D in the 28th week of pregnancy. Acta Obstet Gynecol Scand 1989 68 : 45 7.
15. Thornton JG, Page C, Foote G, Arthur GR, Tovey LAD, Scott JS. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. BMJ 1989 298 : 1671 5.
16. Lee D, Rawlinson VI. Multicentre trial of antepartum low-dose anti-D immunoglobulin. Transfus Med 1995 5 : 15 9.
17. Mayne S, Parker JH, Harden TA, Dodds SD, Beale JA. Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme. BMJ 1997 315 : 1588.
18. MacKenzie I, Bowell P, Gregory H, Pratt G, Guest C, Entwistle CC. Routine antenatal rhesus D immuoglobulin prophylaxis: the results of a prospective 10 year study. Br J Obstet Gynaecol 1999 106 : 492 7.
19. Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database Syst Rev 2000 2 CD000021. DOI: 10.1002/14651858.CD000021.
20. Chilcott J, Lloyd JM, Wight J, Forman K, Wray J, Beverley C, Tappenden P. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technol Assess 2003 7 : iii 62.
21. Engelfriet CP, Reesink HW, Judd WJ, Ulander VM, Kuosmanen M, Koskinen S, Rouger P, Morelati F, Tantalo V, Fujii T, De Haas M, van der Schoot CE, Overbeeke M, Koelewijn J, Bonsel G, Vrijkotte T, Zupanska B, Martin-Vega C, Parra LR, de Silva M, Contreras M, Panzer S, Ulm B, Mayr WR. Current status of immunoprophylaxis with anti-D immunoglobin. Vox Sang 2003 85 : 328 37.
22. Committee prevention pregnancy immunization. Prevention of pregnancy immunization. The Hague : Dutch Health Council 1992 1992/08 : 56 7 [Report in Dutch].
23. Lee D, Craig JS, McClure BG, Tubman TRJ. Revised guidelines advocate two doses of anti-D immunoglobulin for antenatal prophylaxis. BMJ 1998 316 : 1611.
24. Council of Health Insurances. Blood testing in pregnancy. Pregnancy immunization, hepatitis B and lues. Kingston : Council of Health Insurances, National Health Inspection 1998. [Booklet in Dutch].
25. Quality Institute of Healthcare and evidence-based guideline development (CBO). Guide line blood transfusion. Alphen aan den Rijn : Van Zuiden 2004. [Dutch].
26. Ploeg CPB vd, Anthony S, Rijpsta A, Verkerk PH. Process monitoring pre- and postnatal screenings 2003. Leiden : TNO Quality of Life 2006. [Report in Dutch].
27. Engelfriet CP, Ouwehand WH. ADCC and other cellular bioassays for predicting the clinical significance of red cell alloantibodies. Baillieres Clin Haematol 1990 3 : 321 37.
28. Oepkes D, Van Kamp IL, Simon MJ, Mesman J, Overbeeke MA, Kanhai HH. Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization. Am J Obstet Gynecol 2001 184 : 1015 20.
29. Oepkes D, Seaward PG, Vandenbussche FP, Windrim R, Kingdom J, Beyene J, Kanhai HH, Ohlsson A, Ryan G. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med 2006 355 : 156 64.
30. Statistics Netherlands. Available at: http://statline.cbs.nl/StatWeb/ publication/?DM=SLNL&PA=37744NED&D1=0-15&D2=0&D3=(1-11) -1&VW=T
31. Koelewijn JM, Vrijkotte TGM, Van der Schoot CE, Bonsel GJ, Haas M de. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008 48 : 941 52.
32. Bianchi DW, Avent ND, Cosat JM, van der Schoot CE. Noninvasive prenatal diagnosis of fetal rhesus D: ready for prime(r) time. Obstet Gynecol 2005 106 : 841 4.
33. Tovey DLA, Robinson AE. Reduced severity of Rh-haemolytic disease after anti-D immunoglobulin. BMJ 1975 4 : 320 2.
34. Whitfield CR, Raafat A, Urbaniak SJ. Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review. BMJ 1997 315 : 1504 5.